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Abstract
Aims: Integrin-linked kinase (ILK) is a multifunctional kinase linking the extracellular matrix to intracellular signaling
pathways, whose activation in the heart gives rise to a number of functional consequences. The aim of this study is to
demonstrate the therapeutic and survival benefit of cardiac ILK overexpression in a rat model of dilated cardiomyopathy.
Methods and Results: The dilated cardiomyopathy model was generated in rats by intraperitoneal administration of six equal
doses of doxorubicin over a 2 week period. Five weeks after the first injection, echocardiographic analysis demonstrated
impaired cardiac function and, at that point, recombinant adenoviral vector harboring ILK cDNA or vehicle was injected into
the myocardium, and the rats re-studied 4 weeks later. Compared with vehicle injection, ILK treatment ameliorated
inflammatory cell infiltration and cardiomyocyte degeneration, as well as left ventricular dilation and dysfunction. ILK
treatment was also associated with a reduction in apoptosis and an increase in proliferation of cardiomyocytes, as well as
decreased oxidative stress and autophagic vacuole accumulation. Importantly, mortality was lower in rats following ILK
treatment than in those following vehicle injection. In cultured neonatal rat cardiomyocytes, we also found that ILK
overexpression protected against doxorubicin-induced apoptosis, giving rise to an increase in their proliferation.
Conclusions: These data demonstrate for the first time that ILK gene therapy improves cardiac function and survival in a
model of dilated cardiomyopathy, and this may be mediated through suppression of inflammation, prevention of
ventricular remodeling, inhibition of cardiomyocyte apoptosis and autophagy, and stimulation of cardiomyocyte
proliferation.
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Introduction
Despite important advances in medical as well as surgical and
device treatment, chronic heart failure remains an important
worldwide health problem with a poor prognosis [1]. Since it is
characterized by loss of cardiomyocytes combined with impaired
function of the remaining cells and often decreased blood flow
(especially if the underlying etiology is ischemic heart disease), cell
transplantation and gene therapy have been tried and have proved
to be promising strategies. In particular, transplantation of
mesenchymal stem cells [2], bone marrow mononuclear cells [3]
and skeletal myoblasts [4], as well as gene therapy with hepatocyte
growth factor [5], insulin-like growth factor [6] and vascular
endothelial growth factor (VEGF) [7], have been demonstrated to
improve cardiac function and to ameliorate many of the
underlying pathophysiological features.
Integrin-linked kinase (ILK) is a widely expressed serine/
threonine protein kinase and an important biomechanical sensor
which becomes activated upon cell-matrix interaction, thereby
exerting a variety of biological functions including induction of
angiogenesis and regulation of cardiac contractility [8], ventricular
hypertrophy [9], cell proliferation, survival and differentiation
[10,11]. Deletion of ILK from the murine heart results in dilated
cardiomyopathy and spontaneous heart failure [12]. We have
previously shown that ILK gene therapy can attenuate ventricular
remodeling and improve cardiac function in a rat model of
myocardial infarction [13]. Its beneficial effects may be mediated
by increased angiogenesis and cardiomyocyte proliferation as well
as reduced apoptosis. However, at present it is not known whether
ILK gene therapy may improve cardiac function in models of
heart failure and in the absence of underlying cardiac ischemia.
The purpose of the present study was therefore to investigate
whether overexpression of ILK can improve cardiac function of
rats with doxorubicin-induced heart failure, a model of dilated
cardiomyopathy, as well as to determine the mechanisms
underlying its beneficial effects in this condition.
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Ethics Statement
Animal experiments conformed to the Guide for the Care and
Use of Laboratory Animals published by the US National Institutes
of Health (NIH Publication No. 85-23, revised 1996) and was
approved by the Ethics Review Board for Animal Studies of
Nanjing Drum Tower Hospital (DTH ERBA 66.01/026D/2010).
3.1 Recombinant adenovirus construction
Recombinant adenoviral vector containing ILK and hrGFP
cDNA (adeno-ILK) was constructed as previously described [13].
Experiments using adeno-ILK were performed in parallel with
vector harboring neither of these (adeno-null).
3.2 Animal model of dilated cardiomyopathy
A model of dilated cardiomyopathy was generated in 220–250 g
male Sprague-Dawley rats (n=50) with six equal doses of
intraperitoneal doxorubicin hydrochloride (Sigma; total dose
15 mg/kg) administered over 2 weeks as described previously
[4]. Sham-treated rats (n=6) were injected with the same volume
of saline using the same procedure.
3.3 Echocardiography and hemodynamic assessment
Animals were examined 35 days (5 weeks) after the first
doxorubicin injection, and again 28 days (4 weeks) after adenoviral
vector delivery. After anesthesia using a mixture of intraperitoneal
ketamine hydrochloride (50 mg/kg) and diazepam (5 mg/kg), rats
were placed on a warm blanket, and echocardiographic long-axis
and short-axis two-dimensional as well as M-mode tracings were
obtained at the level of the papillary muscles (SONOS model
5500, Hewlett-Packard Co.) using an 8 MHz transducer. Left
ventricular end-systolic diameter (LVESD) and end-diastolic
diameter (LVEDD), as well as interventricular septal thickness in
diastole (IVSd) and LV posterior wall thickness (LVPWT), were all
measured by an observer blinded to the treatment, and averaged
for three consecutive pulsation cycles. Percent left ventricular
fractional shortening (%FS) was calculated as follows:
%FS=(LVEDD-LVESD)/LVEDD6100 (%).
Hemodynamic indices (left ventricular systolic pressure (LVSP),
left ventricular end-diastolic pressure (LVEDP), maximum positive
and negative dP/dt (+dP/dtmax, 2dP/dtmax), and heart rate (HR))
were obtained using a polyethylene catheter (PE 50, Becton-
Dickinson) introduced into the left ventricle via the right carotid
artery and connected to a pressure transducer (MPU-0.5, Nihon
Kohden, Japan) following echocardiography.
3.4 Adenoviral vector delivery
35 days after the first injection, 40 out of 50 doxorubicin-treated
rats (those who had survived and conformed to the heart failure
diagnosis standard) were randomized to treatment with either
adeno-ILK (n=20) or adeno-null (n=20). After induction of
anesthesia as above, rats were intubated and ventilated (Jiangxi
Teli, China) and, following incision in the left fourth intercostal
space, 100 ml in total of adeno-ILK (corresponding to 3610
9 viral
particles (VP)) or adeno-null (3610
9 VP) was injected into the left
ventricle at 10 points, using a syringe attached to a 29-gauge
needle as previously described [4]. Following this, the chest cavity,
muscles and skin were sutured in 3 layers.
3.5 Tissue sample preparation
After hemodynamic assessment at 63 days (9 weeks), hearts were
arrested in diastole by intravenous injection of 2 mol/L KCl. The
myocardium was sliced into three blocks (basal, mid-region, and
apical blocks) and the mid-region portion was cut into two further
blocks, one of which was snap-frozen in liquid nitrogen and stored
at 280uC for subsequent TUNEL examination, whilst the other
was fixed in 4% neutral formalin for 24 h at room temperature
followed by embedding in paraffin wax and cutting into 5 mm
slices for subsequent histologic and immunohistochemical analysis.
The remaining blocks were snap-frozen in liquid nitrogen and
stored at 280uC for western blotting.
3.6 Histologic analysis
Paraffin-embeded slices (5 mm thickness) were stained with
hematoxylin-eosin for morphologic examination or Masson’s
trichrome for interstitial fibrosis determination. Left ventricular
diameter was measured at the level of the papillary muscle as
described [14]. Left ventricular wall thickness, myofilament
density, cardiomyocyte size and collagen volume fraction (CVF)
were measured and analyzed using Image Pro Plus software
(Media Cybernetics), and CVF was calculated as area of Masson’s
trichrome-stained connective tissue divided by total area of the
image as described previously [15].
3.7 ILK expression and activity following adenoviral
vector delivery
Frozen myocardium was homogenized using a Dounce tissue
grinder in lysis buffer consisting of: 10 mmol/L Tris/HCl (pH 7.2),
150 mmol/LNaCl,0.1%SDS,1%sodiumdeoxycholate,5 mmol/
L EDTA, 50 mmol/L NaF, 1 mmol/L sodium orthovanadate, 1%
(v/v) TritonX-100, protease inhibitor cocktail (Roche). Protein
concentrations were quantified by BCA protein assay kit (Pierce).
50 mg protein per sample was separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE), followed by
transferring to polyvinylidene fluoride membranes (Immobilon-P,
Millipore). After incubation with mouse anti-human ILK (1:3000,
BD Transduction Laboratories), rabbit anti-phospho-Akt (Ser473)
(Cell Signaling Technology), rabbit anti-Akt (Cell Signaling
Technology) or mouse anti-GAPDH (1:3000, Kangchen Bio-Tech)
antibodies, peroxidase-conjugated goat anti-mouse IgG or goat
anti-rabbit IgG were used as secondary antibodies (1:5000, Jackson
ImmunoResearch). Bands were visualized by enhanced chemilu-
minescence detection system (Pierce Biotechnology Inc, Rockford,
IL, USA). Results were presented as the ratio of band density values
of ILK to GAPDH or ratio of phospho-Akt to Akt.
3.8 TUNEL assay
We detected apoptosis using DeadEnd Fluorimetric TUNEL
System (Promega) according to the manufacturer’s instructions.
Frozen sections were counterstained with mouse monoclonal a-
sarcomeric actin antibody (1:50, Abcam) while Alexa Fluor 555
goat anti-mouse antibody (1:250, Molecular Probes) was applied as
secondary antibody. Cell nuclei were incubated with DAPI
(Sigma), and then the sections were mounted and analyzed with
a Fluoview 1000 confocal microscope (Olympus, Japan). The
number of TUNEL-positive cardiomyocyte nuclei was manually
determined. The total number of nuclei (exhibited as DAPI-
positive signals) was automatically calculated using Image Pro Plus
software (Media Cybernetics).
3.9 Immunohistochemical analysis of cardiomyocyte
proliferation
Immunohistochemical analysis was performed using antibodies
to phospho-histone H3 (1:100 rabbit anti-phospho-histone H3;
Cell Signaling Technology), Ki-67(1:100 mouse anti-Ki-67,
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Briefly, paraffin-embedded sections were blocked for 30 min with
5% goat serum followed by incubation with primary antibodies
overnight at 4uC. Detection and visualization were performed
using the EnVision detection system (DAKO) after incubation
with secondary antibody for 1 h at 37uC. The ratio of phospho-
histone H3 or Ki67 positive nuclei to the total number of nuclei
was determined and averaged for at least ten fields per sample.
3.10 TNF-a determination
Plasma TNF-a concentrations were determined using rat TNF-
a ELISA kit (Bender MedSystems, Austria, Europe), according to
the manufacturer’s instructions.
3.11 Oxidative stress determination
We detected the concentration of MDA and activity of SOD in
the plasma, both using commercially available kits (Nanjing
Jiancheng Bioengineering Institute), according to the manufactur-
er’s instructions.
3.12 Electron microscopy
Hearts were quickly and carefully dissected from sacrificed rats,
portions of the left ventricle were cut into 1 mm
3 cubes and fixed
with 2% glutaraldehyde in 0.1 mol/L sodium phosphate buffer,
pH 7.4, overnight. The fixed samples were then post-fixed with
1% OsO4, embedded, sectioned and analyzed by transmission
electron microscopy.
3.13 Real-time polymerase chain reaction quantitation of
beclin 1 mRNA
As previously described [16], total RNA was extracted from each
sample using Trizol reagent (Invitrogen) and dissolved in DEPC-
treated water. 2 mg of total RNA was reverse-transcribed into cDNA
using the M-MLV reverse transcriptase (Invitrogen), according to the
manufacturer’s instructions. Real-time polymerase chain reaction
was performed with a 7500 Real-Time PCR system (Applied
Biosystems, CA, USA) using SYBR Premix Ex TaqTM (Takara Bio,







The reaction was performed at 95uC for 30 s, followed by 40
cycles of 95uC for 5 s and 60uC for 34 s. The dissociation stage
was initiated at 95uC for 15 s, followed by 1 cycle of 60uC for
1 min and 95uC for 15 s. The relative gene expression for each
sample was determined using the formula 2
2DDCt, to reflect target
gene expression normalized to GAPDH levels.
3.14 Cardiomyocyte isolation and culture
Primary cultures of neonatal rat cardiomyocytes were prepared
as previously described [17], with some modifications. Briefly,
hearts were obtained from 1- to 2-day-old Sprague-Dawley rats.
The hearts were washed with PBS, and the atria and aorta
discarded. The ventricles were minced into 1–3 mm
3 pieces, and
then digested 4–5 times for 15 min each time with PBS containing
0.1% collagenase (type I, Sigma) and 0.1% trypsin (Sigma), at
37uC. The dissociated cells were collected by centrifugation and
incubated in flasks (Corning) for 60 min at 37uC in a humidified
atmosphere (5% CO2, 95% air), to allow attachment of non-
cardiomyocytes. The non-adherent cardiomyocytes were harvest-
ed and seeded into six-well plates with coverslips. The myocytes
were incubated in Dulbecco’s modified Eagle’s medium (DMEM)
containing 10% FBS, 100 U/ml penicillin, and 100 mg/ml
streptomycin. 5-Bromo-29-deoxyuridine (BrdU; 0.1 mmol/L) was
added to the culture medium for the first 48 h to inhibit
proliferation of non-cardiomyocytes. Cardiomyocytes were then
incubated in DMEM containing 0.5% FBS without BrdU. Using
this method, we obtained cardiomyocytes at 90–95% purity, as
determined by immunoflorescence staining with a monoclonal
antibody against a-sarcomeric actin.
3.15 Adenovirus transfection of cultured cardiomyocytes
Cardiomyocytes were incubated with either adeno-ILK or
adeno-null, 48 h after isolation, at a multiplicity of infection (MOI)
of 100:1, in DMEM containing 0.5% FBS. After 2 h, the media
were removed and replaced with fresh media, and cells cultured
for another 24 h before further experiments as below.
3.16 Cardiomyocyte viability assay
Cell viability was determined by MTT assay as previously
described [18]. For this assay, the cardiomyocytes were seeded into
96-well plates with 2610
4 cells/well. 24 h after transfection,
cardiomyocytes were treated with 1 mmol/L doxorubicin or
vehicle for 24 h, followed by 0.5 mg/mL MTT for 30 min, at
37uC. They were then lysed in 100 ml DMSO. Absorbance was
determined at 570 nm in an ELISA plate reader. All experiments
were performed at least in triplicate, and results expressed as
percentage of the control group.
3.17 Cardiomyocyte apoptosis assay
Cardiomyocytes were seeded into six-well plates with 3610
5
cells/well. 24 h following transfection, cells were treated with
1 mmol/L doxorubicin or vehicle for 24 h. The cardiomyocytes
were then stained with propidium iodide (PI) and annexin V-APC
according to the manufacturer’s instructions (annexin V-APC
apoptosis detection kit, Bender MedSystems, Vienna, Austria).
Apoptotic cells were assessed for annexin V staining by gating on
the fraction of PI-negative cells by flow cytometry (FACScan;
Becton, Dickinson and Company, New Jersey, USA).
3.18 Determination of cardiomyocyte proliferation
96 h after transfection, the cardiomyocytes were fixed with 4%
paraformaldehyde, rinsed with PBS, and permeabilized with 0.1%
Triton X-100 in PBS. Endogenous peroxidase activity was
quenched by incubating coverslips in 3% H2O2 for 10 min. After
blocking with 1% bovine serum albumin , cells were incubated
overnight with a polyclonal antibody against phosphohistone H3
(1:100, Cell Signaling Technology), followed by detection and
visualizion using the EnVision detection system (DAKO), according
to the manufacturer’s instructions. Phosphohistone H3-positive
nuclei and total nuclei were counted per field at 6200 magnifica-
tion. The ratio of phosphohistone H3-positive to total nuclei was
calculated and averaged for at least ten fields per coverslip.
3.19 Statistical analysis
All results were expressed as mean 6 SEM. Comparisons
between groups were performed by unpaired Student’s t test or
ANOVA with Dunnett’s post-test as appropriate. Survival was
estimated from the date of adenoviral vector delivery until death or
4 weeks after adenoviral vector injection. The significance of
differences in survival data was determined using Kaplan-Meier
analysis. All data analysis was performed using SPSS 13.0 software.
Statistical significance was defined as P,0.05 (two-tailed).
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4.1 ILK gene therapy causes increased cardiac ILK
expression and activity
In a previous study [13], we investigated ILK expression in the
rat heart at various intervals following injection of adenovirus
containing ILK and humanized recombinant green fluorescent
protein (hrGFP), from 3 to 35 days. We found that ILK and
hrGFP protein expression rose progressively between 3–14 days,
then declined gradually and tapered off by 35 days. In the present
study, therefore, we examined ILK expression solely at 4 weeks
following injection of this vector (adeno-ILK) or of the
corresponding null adenovirus (adeno-null) into the left ventricle
of rats. Using western blotting, we confirmed that ILK expression
was elevated in the left ventricular tissue of adeno-ILK compared
with adeno-null rats (Fig. 1A). The former group also exhibited an
increase in the ratio of phospho-Akt to total Akt as compared with
the latter group (Fig. 1B), which reflects the increase in ILK
activity since Akt is a downstream target of ILK. This confirmed
successful transfection and overexpression of ILK, as well as an
increase in its kinase activity, in the hearts of adeno-ILK rats.
4.2 ILK gene therapy improves survival, cardiac function
and morphology in rats with doxorubicin-induced
cardiomyopathy
Following doxorubicin administration, rats began to die from day
35 (5 weeks) onwards. At day 35, animals were injected with adeno-
ILK or adeno-null. In both groups, deaths occurred to similar
degrees until day 43 (day 8 following adenoviral vector delivery),
whereasthey diverged from that point untiltheendofthe study(day
63 following doxorubicin administration or day 28 following
adenoviral vector delivery): in adeno-ILK rats, cumulative survival
plateaued at 60% from day 58 (or day 23 following adenoviral
vector delivery) onwards, whereas it continued to decrease to a
plateau of 35% in adeno-null rats which was attained at day 59 (day
24 following adenoviral vector delivery) until the end of the study
(Fig. 1C). No deaths occurred in the parallel group of rats given
saline only (instead of doxorubicin). Animals not surviving to 9
weeks showed gross pathological changes consistent with cardiac
failure: hepatic congestion, pleural effusions, ascites. No animal
treated with ILK showed evidence of neoplasia in the liver, kidney
or spleen up to the 9 week time point.
Systolic function, as evaluated from ejection fraction and %
fractional shortening on echocardiography, deteriorated from
baseline over the 5 weeks following initiation of doxorubicin
treatment, and this wasaccompanied by an increaseinleft ventricular
end-systolic and end-diastolic dimensions. In the surviving animals
who received adeno-ILK at 5 weeks, cardiac function and dimensions
at week 9 were not different from those at week 5, whereas in the
adeno-null animals all of these parameters continued to deteriorate
(Fig. 2 A–D). In line with these findings, we found on hemodynamic
analysis that, four weeks after the adenoviral injection, there was an
increase in left ventricular systolic pressure and a decrease in left
ventricular end-diastolic pressure in the adeno-ILK compared with
the adeno-null animals; and the adeno-ILK group also showed a
greater maximum +dP/dt and a lower maximum 2dP/dt as
compared with the adeno-null group (Fig. 2 E–G).
Following sacrifice and dissection, the hearts of adeno-null rats
were found macroscopically to be larger and more spherical than
those of both adeno-ILK and control (saline-treated) rats (Fig. 3A).
Preservation of left ventricle cavity size and wall thickness was
demonstrated by decreased left ventricular diameter combined
with increased wall thickness in the adeno-ILK as compared to the
adeno-null group, reflecting attenuation of left ventricular dilation
and global remodeling by ILK treatment (Fig. 3B). Microscopi-
cally, myofilament density was increased, and both cardiomyocyte
size and interstitial fibrosis (as determined from collagen volume
fraction on Masson’s trichrome staining) were decreased, in
adeno-ILK as compared with adeno-null rats (Fig. 3 C–D).
4.3 ILK gene therapy inhibits apoptosis and increases
proliferation of left ventricular cardiomyocytes in rats
with doxorubicin-induced cardiomyopathy
TUNEL analysis and phosphohistone-H3 expression together
with Ki-67 expression were performed to quantify cardiomyocyte
apoptosis and proliferation respectively. We found that the
percentage of TUNEL-positive cardiomyocytes was decreased in
the adeno-ILK compared to the adeno-null group (Fig. 4). On the
Figure 1. ILK gene therapy increases left ventricular ILK expression and activity, improves survival in doxorubicin-induced
cardiomyopathy. A, Western blot showing elevated ILK protein expression in the left ventricular tissue of the adeno-ILK group as compared with
the adeno-null group. The blot also shows green fluorescent protein (GFP) expression in adeno-ILK, but not adeno-null, treated hearts.
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression is also shown as a housekeeping protein. B, Western blot showing left ventricular
phospho-Akt (pAkt) and Akt expression. The ratio of pAkt to Akt was increased following adeno-ILK delivery relative to adeno-null control, in line with
increased Akt phosphorylation due to elevated ILK activity. C, Kaplan-Meier survival curve for doxorubicin-treated rats treated with adeno-ILK (n=20)
and adeno-null (n=20) (p=0.093).
doi:10.1371/journal.pone.0031279.g001
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cardiomyocytes were both found to increase in the adeno-ILK
group relative to the adeno-null group, suggesting that ILK
treatment increases cardiomyocyte proliferation (Fig. 5). To
investigate whether the proliferating cells were of stem cell origin,
we examined Sca-1 positive cells but found no difference in this
between the adeno-null and adeno-ILK groups (data not shown).
4.4 Doxorubicin treatment increases circulating markers
of inflammation and oxidative stress, and these are
inhibited by cardiac ILK gene therapy
Inflammatory cell infiltration and cardiomyocyte degeneration,
as evidenced by CD45 and hematoxylin-eosin staining, were
ameliorated by ILK treatment (Fig. 6 A–B). Plasma tumor necrosis
factor-a (TNF-a) concentration, a marker of systemic inflamma-
tion, was higher in doxorubicin- than saline-treated rats, and this
increase was attenuated in part by cardiac ILK overexpression
(Fig. 6C). Doxorubicin also gave rise to an increase in oxidative
stress, as evidenced by a rise in plasma malondialdehyde (MDA)
concentration and a decrease in plasma superoxide dismutase
(SOD) activity compared with the saline-treated rats; ILK
overexpression abrogated the increase in plasma MDA as well
as the decrease in plasma SOD activity, compared with the adeno-
null controls (Fig. 6 D–E).
4.5 Doxorubicin treatment causes cardiac myofibril
degeneration and autophagic vacuole formation, effects
which are inhibited by ILK gene therapy
Compared with the hearts of rats treated with saline,
doxorubicin gave rise to accumulation of autophagic vacuoles,
altered structural integrity and extensive degeneration of myofi-
brils. The hearts from adeno-ILK animals displayed a decrease in
the number of autophagic vacuoles and a finer mitochondrial
ultrastructure (Fig. 7A).
Since the formation of the autophagasome is critically dependent
on beclin 1, we also quantitated beclin 1 mRNA expression by real-
time PCR. We found this to be increased 1.8-fold in the hearts of
doxorubicin-treated rats administered adeno-null, as compared to
control (saline-treated) rats. By contrast, this increase was abrogated
in doxorubicin-treated rats given adeno-ILK (Fig. 7B).
Figure 2. Cardiac ILK gene therapy improves cardiac function and hemodynamics in doxorubicin-induced heart failure. Shown are
left ventricular end-diastolic diameter (LVEDD, A), left ventricular end-diastolic diameter (LVESD, B), ejection fraction (EF, C), fractional shortening (FS,
D), 6dP/dtmax (E), left ventricular end-diastolic pressure (LVEDP, F) and left ventricular systolic pressure (LVSP, G). n=20 at 5 weeks and n=12 at 9
weeks in the adeno-ILK group, whilst n=20 at 5 weeks and n= 7 at 9 weeks in the adeno-null group. *P,0.05 versus adeno-null group.
doi:10.1371/journal.pone.0031279.g002
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promotes proliferation, of cultured neonatal rat
cardiomyocytes
Neonatal rat cardiomyocytes were isolated and cultured; we
found that .90% of the cells in culture exhibited immunocyto-
chemical staining for alpha sarcomeric actin in the cytoplasm,
confirming their nature as cardiomyocytes as well as their high
degree of purity. Incubation of cells with 1 mmol/L doxorubicin
for 24 h resulted in decreased cell viability, as measured by 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) as-
say; cardiomyocytes transfected with adeno-ILK prior to addition
of doxorubicin exhibited enhanced cell viability relative to adeno-
null transfected cells (Fig. 8A).
Cardiomyocyte apoptosis was increased in the presence of
doxorubicin. As shown in Fig. 8B, the early apoptotic marker annexin
V was increased in adeno-null transfected cardiomyocytes, but this
change was attenuated in adeno-ILK transfected cells, in the presence
of doxorubicin. Furthermore, a marked increase in phosphohistone
H3-positive cells was found in the adeno-ILK group as compared to
the adeno-null group (Fig. 8C), indicating an increase in their rate of
proliferation in the former group compared to the latter.
Discussion
The present study provides evidence of benefit for ILK
treatment on the progression of heart failure caused by
doxorubicin-induced cardiomyopathy, a non-ischemic cardiomy-
Figure 3. ILK gene therapy prevents left ventricular dilation, remodeling and interstitial fibrosis in doxorubicin-induced heart
failure. A, Specimens showing effect of ILK treatment on heart size and shape following doxorubicin. B, Hematoxylin-eosin staining of myocardial
sections 4 weeks after adeno-ILK or adeno-null treatment, with analysis of cardiac remodeling by quantification of left ventricular (LV) diameter and
wall thickness. n=6 per group. C, Myofilament density and cardiomyocyte size in adeno-ILK and adeno-null groups. n=6 per group. Scale bars:
100 mm (left panels, 2006), 50 mm (right panels, 4006). D, Masson’s trichrome staining showing infiltration by inflammatory cells and myocardial
fibrosis in adeno-ILK and adeno-null animals. n=6 per group. Scale bars: 5 mm. * P,0.05 vs. adeno-null.
doi:10.1371/journal.pone.0031279.g003
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Triple-staining with TUNEL (green, arrows), anti-a-sarcomeric actin antibody (red) and DAPI (blue) in left ventricle. B, Quantification of TUNEL-positive
cardiomyocytes in left ventricle from adeno-ILK and adeno-null treated rats. n=6 per group. *P,0.05 versus adeno-null group. Scale bars: 20 mm.
doi:10.1371/journal.pone.0031279.g004
Figure 5. Cardiac ILK gene therapy increases left ventricular cardiomyocyte proliferation in doxorubicin-induced heart failure. A–B,
Phosphohistone-H3 staining for mitotic analysis (brown, arrows), in adeno-ILK (A) and adeno-null (B) treated rats. C-D, Ki-67 staining showing more
positive cells (brown, arrows) in adeno-ILK tissue sections (C) than in adeno-null sections (D). E–F, Accumulated results showing phosphohistone-H3
(E) or Ki-67 (F) positive cardiomyocytes in adeno-ILK and adeno-null groups. n=6 per group. *P,0.05 versus adeno-null group. Scale bars: 100 mm.
doi:10.1371/journal.pone.0031279.g005
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dilated cardiomyopathy in humans. Treatment with adeno-ILK
was started 5 weeks after the first doxorubicin injection, so that the
rescue effects could be assessed once cardiac function had already
been compromised. In our model, the cardiomyopathy was severe,
as evidenced by a clear increase in mortality, advanced signs of
cardiac dysfunction, and significant histopathologic changes in the
doxorubicin -treated animals. We found that ILK administration
improved the prognosis of dilated cardiomyopathy in terms of
survival, with associated marked improvements in both functional
and structural parameters after ILK treatment: enhanced cardiac
function, relatively preserved left ventricular diameter and wall
thickness, attenuated interstitial fibrosis, decreased cardiomyocyte
apoptosis, increased cardiomyocyte proliferation, decreased in-
flammatory cell infiltration, reduced oxidative stress and dimin-
ished autophagic vacuole accumulation.
As a critical component of the cardiac mechano-sensor/
transduction mechanism, ILK functions as a scaffold linking cell-
surface integrins to intracellular signaling pathways and the actin
cytoskeleton. ILK is activated by mechanical stretch and growth
factors, and thereby affects important signaling pathways within the
cardiomyocyte which induce cell survival, promote angiogenesis
and increase cardiomyocyte contractility [8]. Targeted knock-out of
ILK in the murine heart results in disaggregation of cardiomyocytes
and spontaneousdilated cardiomyopathy, suggesting that ILKplays
an important part in protecting the heart from cardiomyopathy and
heart failure. ILK increases cardiomyocyte hypertrophy and
contractility by upregulating atrial natriuretic peptide and VEGF
expression [8], which also both exert protective effects on cardiac
function [19]. Previous studies have shown that ILK can induce
angiogenesis, cell growth, proliferation, survival and differentiation
in non-cardiac cells [10], whilst we have previously shown these
Figure 6. Cardiac ILK gene therapy prevents inflammation and cardiomyocyte degeneration, and improves markers of systemic
inflammation and oxidative stress, in doxorubicin-induced heart failure. A–B, Hematoxylin-eosin (A) and CD45 staining (brown) (B) of
myocardium 4 weeks following adeno-ILK or adeno-null treatment, showing effects on cardiomyocyte degeneration (myofibrillar derangement and
disruption) and inflammatory cell infiltration. C–E, Plasma tumor necrosis factor-a (TNF-a) concentration (C), malondialdehyde concentration (D) and
superoxide dismutase activity (E), in control (saline-treated) as well as doxorubicin-treated rats receiving either adeno-ILK or adeno-null. n=6 per
group. *, ** P,0.05 and ,0.01 respectively. Scale bars: 100 mm.
doi:10.1371/journal.pone.0031279.g006
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context of myocardial infarction [13].
Myocardial apoptosis is a major determinant of reduction in
cardiac function [20]. In a model of acute myocardial infarction,
we have previously demonstrated that ILK treatment reduces
cardiomyocyte apoptosis both in the border and more remote
zones [13]. In the present study, we have similarly found that ILK
treatment improves cardiac function secondary to reduced
apoptosis in doxorubicin-induced cardiomyopathy. Since ILK
overexpression can promote activation of Akt [12], which in turn
can inhibit cardiomyocyte apoptosis and improve cardiac
contractility [21], we postulate that ILK exerts these beneficial
effects through increasing the phosphorylation and hence
activation of Akt.
Irreversible cardiomyocyte loss, coupled with limited regener-
ative capacity and ability to differentiate, following a variety of
environmental stresses and external injuries are believed to be
important factors leading to the progression of cardiac dysfunc-
tion. Previous studies have shown that ILK overexpression can
promote cardiac stem cell amplification in vitro [22] as well as
induce cyclin D2 expression [23], which can promote cardiomy-
ocyte regeneration in injured hearts [24]. In the present study, we
observed increased cardiomyocyte proliferation in the left ventricle
in response to ILK treatment, and this is likely also to contribute to
the observed amelioration of cardiac function. Our experiments
provided no evidence that this increase in cardiomyocyte
proliferation in response to ILK was explained by stem cell
differentiation, and this is consistent with previous studies [25].
We observed that doxorubicin induced myocardial fibrosis and
inflammatory cell infiltration, and that ILK treatment prevented
both of these processes. It is already established that elevation in
inflammatory mediators in the heart is associated with cardiac
dysfunction [26], but it has been contentious as to whether TNF-a
mediates inflammation and fibrosis in doxorubicin-induced
cardiomyopathy and the failing heart [27–30]. We here report
decreased plasma TNF-a concentration in adeno-ILK compared
to adeno-null treated rats, which is in line with the observed
reduction in inflammatory cell infiltration in the adeno-ILK group;
the underlying mechanism, however, requires further investigation.
Many mechanisms have been proposed to explain doxorubicin-
mediated cardiotoxicity, among which the generation of reactive
oxygen species (ROS) and calcium overload are considered
perhaps the most important [31–33]. ROS are also considered
important in the pathophysiology and progression of idiopathic
dilated cardiomyopathy [34]. ROS cause lipid peroxidation and
resultant generation of degradation products such as MDA. On
the other hand, the activities of antioxidant systems such as SOD
decrease under conditions of oxidative stress. In the present study,
an increase in MDA and decrease in SOD activity in the plasma
were observed in doxorubicin-treated rats, which were restored by
ILK treatment, indicating that cardiac ILK gene therapy reverses
ROS overproduction and subsequent oxidative stress.
Autophagy is considered physiologically important for the
maintenance of normal cardiovascular morphology and function,
whilst excessive autophagy by various factors contributes to the
induction and exacerbation of several types of cardiomyopathy
Figure 7. Cardiac ILK gene therapy inhibits doxorubicin-induced autophagy. A, Electron micrographs showing autophagic vacuole (arrow)
formation in cardiomyocyte of a doxorubicin-treated rat administered adeno-null, and lack of this in another rat administered adeno-ILK and in a
control (saline-treated) rat. Scale bar, 2 mm. B, Effect of doxorubicin treatment on cardiac beclin 1 mRNA expression, and the effect of ILK treatment
on this. Beclin 1 mRNA expression levels were normalized first to GAPDH and then displayed relative to levels in the control group using the2
2DDCt
method. n=6 per group. *P,0.05.
doi:10.1371/journal.pone.0031279.g007
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displayed a decreased number of autophagic vacuoles compared to
those receiving adeno-null. In line with this finding, we also observed
a reduction in beclin 1 (a Bcl-2-interacting protein) expression in the
adeno-ILK group. Our findings suggest that cardiac ILK treatment
can reduce autophagic activity, and this may contribute to delaying,
or even reversing, the progression of heart failure.
In the present study, we found both increased expression and
kinase activity of ILK in the heart after adeno-ILK delivery. We
evaluated the safety of ILK-treatment at four weeks after
adenoviral delivery, especially in view of its propensity to induce
angiogenesis and proliferation, but no neoplasia was detected in
the liver, kidney or spleen of treated rats. Our study therefore
suggests that ILK gene therapy beneficially affects left ventricular
structure and function in doxorubicin-induced cardiomyopathy, as
well as improving survival. Its potential usefulness in dilated
cardiomyopathy in humans remains to be determined.
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